AURORA NAVAJAS GUTIERREZ-rekin lankidetzan egindako argitalpenak (37)

2023

  1. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

    Acta Neuropathologica, Vol. 145, Núm. 5, pp. 651-666

2019

  1. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 564-569

2018

  1. Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk

    Oncotarget, Vol. 9, Núm. 33, pp. 22907-22914

  2. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment

    Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412

  3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 18, Núm. 6, pp. 704-712

  4. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity

    Epigenomics, Vol. 10, Núm. 4, pp. 409-417

2017

  1. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population

    PLoS ONE, Vol. 12, Núm. 5

2016

  1. MIR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 26, Núm. 11, pp. 517-525

  2. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 17, Núm. 7, pp. 731-741

2015

  1. Disseminated fusariosis and hematologic malignancies, a still devastating association. Report of three new cases

    Revista Iberoamericana de Micologia, Vol. 32, Núm. 3, pp. 190-196

  2. La Unidad de Hematologíay Oncología Pediátricas del Hopsital Universitario Cruces (1992-2015)

    Revista española de pediatría: clínica e investigación, Vol. 71, Núm. 4, pp. 217-222

2014

  1. Errors in the interpretation of copy number variations due to the use of public databases as a reference

    Cancer Genetics, Vol. 207, Núm. 4, pp. 164-167

  2. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility

    Pediatric Research, Vol. 75, Núm. 6, pp. 767-773

  3. Pharmacogenetics of MicroRNAs and MicroRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. Intron 3 of the ARID5B gene: A hot spot for acute lymphoblastic leukemia susceptibility

    Journal of Cancer Research and Clinical Oncology, Vol. 139, Núm. 11, pp. 1879-1886

  2. Polymorphisms in the methotrexate transport pathway: A new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 23, Núm. 2, pp. 53-61

2011

  1. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia

    Pediatric Blood and Cancer, Vol. 57, Núm. 4, pp. 612-619

2009

  1. Nódulos subcutáneos como forma de presentación de síndrome linfoproliferativo maligno

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 71, Núm. 2, pp. 148-152

2008

  1. Genetic polymorphisms associated with adverse events in childhood acute lymphoblastic leukaemia treated with SHOP-2005 protocol

    EJC SUPPLEMENTS

2004

  1. Near fatal cerebellar swelling in familial hemophagocytic lymphohistiocytosis

    Pediatric Neurology, Vol. 30, Núm. 5, pp. 361-364